Shares of Intellia Therapeutics sank 8.8% to $13.61 on June 16, giving back a chunk of the prior session's 23.2% spike — a textbook profit-taking selloff after a catalyst-driven surge. The bigger question for shareholders: does one blockbuster clinical readout justify a lasting revaluation of a company still burning through cash with no approved product?
A One-Time Treatment Posted Landmark Trial Numbers
On June 13, the company announced additional positive results from its global Phase 3 trial of its CRISPR-based gene-editing therapy for hereditary angioedema (HAE), a rare genetic condition causing severe, unpredictable swelling attacks. The trial showed an 87% reduction in monthly attacks versus placebo, and 62% of treated patients were entirely attack-free and therapy-free over six months, compared with just 11% on placebo . Results were simultaneously published in the New England Journal of Medicine — a credibility stamp that matters for FDA reviewers and prescribers alike.
The FDA Clock Is Ticking Toward a 2027 Launch
Intellia plans to complete its rolling application to the FDA in the second half of 2026, targeting a U.S. launch in the first half of 2027 . The therapy carries a special FDA designation that allows the company to submit its application in pieces and may qualify for accelerated review . That timeline is tight; any manufacturing or data hiccup could push commercialization further out for a company still generating no meaningful product revenue.
Cash Is Sufficient — Barely
Cash and securities stood at $517.2 million as of March 31, plus roughly $207 million raised in an April stock offering, extending the runway into 2028 . The Q1 net loss narrowed to $96.2 million from $114.3 million a year ago , but the company still burns nearly $100 million per quarter. If the launch slips or uptake disappoints, another dilutive capital raise looms.
The Market Opportunity Is Real, But Crowded
The global HAE treatment market is valued at roughly $6.5 billion and projected to grow at a 17% annual clip through 2034 . But Intellia won't have the field to itself: Ionis won FDA approval last year for an RNA-based HAE prevention therapy , and KalVista launched the first oral on-demand HAE treatment in 2025 . Intellia's pitch — a single dose that may replace lifelong injections — is compelling, but pricing and payer acceptance for a one-time gene-editing treatment remain uncharted territory. At a $2.08 billion market cap , the stock is priced as if much can still go wrong.